Research programme: recombinant mycobacteria - BacilligenAlternative Names: rBGC; rMB
Latest Information Update: 16 Jul 2016
At a glance
- Originator Bacilligen
- Class Bacterial vaccines; Recombinant proteins
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Bladder cancer; Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Bladder-cancer in USA (Parenteral)
- 13 Nov 2007 Preclinical trials in Solid tumours in USA (Parenteral)